Trough level of infliximab is useful for assessing mucosal healing in Crohn's disease: a prospective cohort study

BACKGROUND/AIMS: Decreased trough levels of infliximab (TLI) and antibodies to infliximab (ATI) are associated with loss of response (LOR) in Crohn's disease. Two prospective studies were conducted to determine whether TLI or ATI better correlates with LOR (Study 1), and whether TLI could becom...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Izdano u:Intest Res
Glavni autori: Koga, Akihiro, Matsui, Toshiyuki, Takatsu, Noritaka, Takada, Yasumichi, Kishi, Masahiro, Yano, Yutaka, Beppu, Takahiro, Ono, Yoichiro, Ninomiya, Kazeo, Hirai, Fumihito, Nagahama, Takashi, Hisabe, Takashi, Takaki, Yasuhiro, Yao, Kenshi, Imaeda, Hirotsugu, Andoh, Akira
Format: Artigo
Jezik:Inglês
Izdano: Korean Association for the Study of Intestinal Diseases 2018
Teme:
Original Article
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC5934595/
https://ncbi.nlm.nih.gov/pubmed/29743835
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.5217/ir.2018.16.2.223
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!

Similar Items